A randomized, double-blind, placebo-controlled trial of a glycine antagonist in neuropathic pain

Neurology

Volumn 59, Issue 11, 2002, Pages 1694-1700

  Wallace, Mark S ^a,j   Rowbotham, M C ^b   Katz, N P ^c   Dworkin, R H ^d   Dotson, R M ^e   Galer, B S ^f   Rauck, R L ^g   Backonja, M M ^h   Quessy, S N ⁱ   Meisner, P D ⁱ  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^e MAYO CLINIC   (United States)

^f ENDO PHARMACEUTICALS INC   (United States)

^g WAKE FOREST BAPTIST HEALTH   (United States)

^h UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

ⁱ GLAXOSMITHKLINE   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

4,6 DICHLORO 3 (2 OXO 1 PHENYL 3 PYRROLIDINYLIDENEMETHYL) 1H INDOLE 2 CARBOXYLIC ACID; GLYCINE RECEPTOR; GLYCINE RECEPTOR ANTAGONIST; PLACEBO;

ADULT; AGED; ALLODYNIA; ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; COMPLEX REGIONAL PAIN SYNDROME; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEUROPATHY; DISEASE MODEL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; FEMALE; HUMAN; HYPERALGESIA; INCIDENCE; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; NEUROPATHIC PAIN; PATIENT SATISFACTION; PERIPHERAL NERVE INJURY; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SAFETY; SIDE EFFECT; VISUAL ANALOG SCALE;

EID: 0037058809     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000036273.98213.34     Document Type: Article

References (21)

1. Ozawa S, Kamiya H, Tsuzuki K. Glutamate receptors in the mammalian central nervous system. Prog Neurobiol 1998;54: 581-618.
2. Backonja M, Arndt G, Gombar K, Check B, Zimmermann M. Response of chronic neuropathic pain syndromes to ketamine: A preliminary study. Pain 1994;56:51-57.
3. Eide P, Jorum E, Stubhaug A, Bremnes J, Breivik H. Relief of post-hepetic neuralgia with the N-methyl-aspartic acid receptor antagonist ketamine: A double-blind cross-over comparison with morphine, and placebo. Pain 1994;58:347-354.
4. Leung A, Wallace M, Ridgeway R, Yaksh T. Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain 2001;91:177-187.
5. Max M, Byas-Smith M, Gracely R, Bennett G. Intravenous infusion of the NMDA antagonist, ketamine, in chronic posttraumatic pain with allodynia: A double-blind comparison to alfentanil and placebo. Clin Neuropharmacol 1995;18:360-368.
6. Pud D, Eisenberg E, Spitzer A, Adler R, Fried G, Yarnitsky D. The NMDA receptor antagonist amantadine reduces surgical neuropathic pain in cancer patients: A double blind, randomized, placebo controlled trial. Pain 1998;75:349-354.
7. Nelson K, Park K, Robinovitz E, Tsigos C, Max M. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology 1997;48:1212-1218.
8. Haines D, Gaines S. N of 1 randomized controlled trials of oral ketamine in patients with chronic pain. Pain 1999;83:283-287.
9. Enarson MC, Hays H, Woodroffe MA. Clinical experience with oral ketamine. J Pain Sympt Manage 1999;17:384-386.
10. Kolhekar R, Meller S, Gebhart G. N-Methyl-D-aspartate receptor-mediated changes in thermal nociception: Allosteric modulation at glycine and polyamine recognition sites. Neuroscience 1994;63:925-936.
11. Quartaroli M, Carignani C, Dal Forno G, et al. Potent antihyperalgesic activity without tolerance produced by glycine site antagonist N-methyl-D-aspartate receptor GV196771A. J Pharmacol Exp Ther 1999;290:158-169.
12. Danyz W, Parsons CG. Glycine and NMDA receptors: Physiological significance and possible therapeutic applications. Pharmacol Rev 1998;50:597-664.
13. Bordi F, Quartaroli M. Modulation of nociceptive transmission by NMDA/glycine site receptor in the ventroposterolateral nucleus of the thalamus. Pain 2000;84:213-224.
14. Belfrage M, Sollevi A, Segerdahl M, Sjolund K, Hansson P. Systemic adenosine infusion alleviates spontaneous and stimulus evoked pain in patients with peripheral neuropathic pain. Anesth Analg 1995;81:713-717.
15. Mao J, Price D, Hayes R, Lu J, Mayer D. Differential roles of NMDA and non-NMDA receptor activation in induction and maintenance of thermal hyperalgesia in rats with painful peripheral mononeuropathy. Brain Res 1992;598:271-278.
16. Mao J, Price D, Hayes R, Lu J, Mayer D, Frenk H. Intrathecal treatment with dextrorphan or ketamine potently reduces pain-related behaviours in a rat model of peripheral mononeuropathy. Brain Res 1993;605:164-168.
17. Yamamoto Y, Yaksh T. Studies on the spinal interaction of morphine and the NMDA antagonist MK-801 on the hyperesthesia observed in a rat model of sciatic mononeuropathy. Neurosci Lett 1992;135:67-70.
18. Ochoa JL, Torebjork HE. Sensations evoked by intraneural microstimulation of C nociceptor fibres in human skin nerves. J Physiol 1989;415:583-599.
19. Torebjork HE, Vallbo AB, Ochoa JL. Intraneural microstimulation in man. Its relation to specificity of tactile sensations. Brain 1987;110:1509-1529.
20. Yarnitsky D, Ochoa JL. Warm and cold specific somatosensory systems. Psychophysical thresholds, reaction times and peripheral conduction velocities. Brain 1991;114:1819-1826.
21. Coderre T, Van Empel I. The utility of excitatory amino acid (EAA) antagonists as analgesic agents. I. Comparison of the antinociceptive activity of various classes of EAA antagonists in mechanical, thermal and chemical nociceptive tests. Pain 1994;59:345-352.